Qiagen
Ad
related to: Sartorius AGDiscover our analytical data package that defines the characteristics of the product. This analysis is needed at every step, from clone selection to commercial manufacturing.
Search results
Sartorius is part of the solution. We help to ensure that new scientific discoveries can be translated more quickly into effective patient care. With technologies, platforms and partnerships for a common goal: better health for more people.
Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest (Blue chip) stock market index.
Sartorius expects dynamic development with double-digit growth in sales revenue and sustained high profitability in the current year as well. Based on the company’s strong performance in fiscal 2021, management also raised its mid-term forecast for profitability again.
Based on the slight recovery in demand since the end of the third quarter of 2023 and the market outlook forecast by industry observers, Sartorius expects to grow profitably in 2024 and beyond. 2024
Sartorius has continued on its fast growth trajectory begun at the start of the year, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.
Sartorius is a leading international partner for the biopharma sector, offering products and services for drug development and production. Learn about its financial performance, growth strategy, corporate structure and investor relations.
Jun 19, 2024 · The latest international Sartorius AG news and views from Reuters - one of the world's largest news agencies.
